Real-world multicenter evidence on Nefecon for attenuating proteinuria and kidney function decline in IgA nephropathy
IntroductionTargeted-release budesonide (Nefecon) has demonstrated efficacy in IgA nephropathy (IgAN) trials, yet real-world data across disease severity spectrum remains limited.MethodsThis multicenter, retrospective cohort study included 148 biopsy-p…